Dr. James Mohler on Androgen Levels in Prostate Cancer

James Mohler, MD
Published: Wednesday, Jan 30, 2013

James Mohler, MD, Associate Director and Senior-Vice President for Translational Research, Chair, Department of Urology, Professor of Oncology, Roswell Park Cancer Institute, explains the progress needed to better understand androgen receptors. An older study found that patients with elevated circulating levels of adrenal androgens responded better and longer to ketoconazole. The question is whether or not the same principle can be applied to abiraterone.

Theoretically, Mohler says, an oncologist could biopsy a patient's prostate gland, measure tissue levels of androgens, and determine which anti-androgen agent would work best. As a long-term goal, Mohler sees the need to learn more about how drugs work and how they fail.

James Mohler, MD, Associate Director and Senior-Vice President for Translational Research, Chair, Department of Urology, Professor of Oncology, Roswell Park Cancer Institute, explains the progress needed to better understand androgen receptors. An older study found that patients with elevated circulating levels of adrenal androgens responded better and longer to ketoconazole. The question is whether or not the same principle can be applied to abiraterone.

Theoretically, Mohler says, an oncologist could biopsy a patient's prostate gland, measure tissue levels of androgens, and determine which anti-androgen agent would work best. As a long-term goal, Mohler sees the need to learn more about how drugs work and how they fail.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x